{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T07:04:04Z","timestamp":1784358244018,"version":"3.55.0"},"reference-count":45,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Orthop Surg (Hong Kong)"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To investigate the level of miR-550a-3p in patients with osteoporosis (OP), osteoporotic fractures (OPF), and healthy controls, and diagnostic value for OP, OPF, and fracture healing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>246 OP patients (120 OP, 126 OPF) and 113 healthy controls were enrolled. Serum miR-550a-3p levels were detected by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Pearson analysis assessed correlations with T-score, 25-(OH) Vitamin D, receptor activator of nuclear factor-\u03baB ligand (RANKL), and osteoprotegerin (OPG). OPF patients were followed for 6 months (normal\/delayed healing groups). Receiver operating characteristic (ROC) curves and logistic regression analyzed diagnostic value.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>miR-550a-3p expression was significantly lower in OP and OPF groups than in controls, with the lowest level in OPF patients. It effectively distinguished OP from controls (AUC = 0.899) and OPF from OP (AUC = 0.911). miR-550a-3p was positively correlated with T-score, 25-(OH) Vitamin D, and OPG, and negatively correlated with RANKL. In OPF patients, miR-550a-3p was lower in the delayed healing (DH) group (AUC = 0.851) and identified as an independent factor for delayed healing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>miR-550a-3p exhibits potential as a biomarker for diagnosing OP and OPF, and for predicting fracture healing outcomes in OPF patients, providing a novel tool for clinical management of osteoporotic fractures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10225536261441917","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:47:36Z","timestamp":1784126856000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of diagnostic efficacy and fracture healing predictive value of miR-550a-3p in patients with osteoporotic fractures"],"prefix":"10.1177","volume":"34","author":[{"given":"Binbin","family":"Fan","sequence":"first","affiliation":[{"name":"Guangdong Second Provincial General Hospital (Guangdong Provincial Emergency Hospital)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Li","sequence":"additional","affiliation":[{"name":"Pan\u2019an People\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1657-5812","authenticated-orcid":false,"given":"Haitao","family":"Xu","sequence":"additional","affiliation":[{"name":"Zhucheng People\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaiwei","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Shuyang Hospital of TCM"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S307633"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2024.1289730"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cdtm.2015.02.006"},{"key":"e_1_3_3_5_2","volume-title":"Denosumab (prolia): treatment to increase bone mass in men with osteoporosis at high risk for fracture; or who have failed or are intolerant to other available osteoporosis therapy","year":"2015","unstructured":"Canadian Agency for Drugs and Technologies in Health. Denosumab (prolia): treatment to increase bone mass in men with osteoporosis at high risk for fracture; or who have failed or are intolerant to other available osteoporosis therapy, 2015."},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.679914"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.882895"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/08941939.2022.2048926"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13018-025-06291-0"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-022-00799-9"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2022.2031428"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2017.01.028"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0097098"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.971"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22844-2"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2365"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000020904"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering11060525"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(87)90021-2"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1006\/meth.2001.1262"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-12-227"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13018-025-06315-9"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/304178"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12893-024-02322-5"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6610116"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0298086"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1080\/08941939.2024.2421826"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.3390\/nu16081220"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-022-00460-7"},{"key":"e_1_3_3_30_2","first-page":"4156","article-title":"MiR-550a-3p promotes non-small cell lung cancer cell proliferation and metastasis through down-regulating TIMP2","volume":"22","author":"Yang JZ","year":"2018","unstructured":"Yang JZ, Bian L, Hou JG, et al. MiR-550a-3p promotes non-small cell lung cancer cell proliferation and metastasis through down-regulating TIMP2. Eur Rev Med Pharmacol Sci 2018; 22: 4156\u20134165. https:\/\/doi.org\/10.26355\/eurrev_201807_15408","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10793"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-024-05622-8"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20115976"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-011-9555-8"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.3390\/nu11122848"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15174367"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/8792"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioactmat.2025.04.013"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2020.100740"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2012.03.021"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27165"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6882-14-35"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.2741\/4273"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12033-021-00322-x"},{"key":"e_1_3_3_45_2","first-page":"2519","article-title":"MiR-133a inhibits fracture healing via targeting RUNX2\/BMP2","volume":"22","author":"Peng H","year":"2018","unstructured":"Peng H, Lu SL, Bai Y, et al. MiR-133a inhibits fracture healing via targeting RUNX2\/BMP2. Eur Rev Med Pharmacol Sci 2018; 22: 2519\u20132526. https:\/\/doi.org\/10.26355\/eurrev_201805_14914","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_3_3_46_2","first-page":"5797","article-title":"Hsa-miR-203 inhibits fracture healing via targeting PBOV1","volume":"22","author":"Zhang SY","year":"2018","unstructured":"Zhang SY, Gao F, Peng CG, et al. Hsa-miR-203 inhibits fracture healing via targeting PBOV1. Eur Rev Med Pharmacol Sci 2018; 22: 5797\u20135803. https:\/\/doi.org\/10.26355\/eurrev_201809_15905","journal-title":"Eur Rev Med Pharmacol Sci"}],"container-title":["Journal of Orthopaedic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10225536261441917","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10225536261441917","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10225536261441917","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T06:47:29Z","timestamp":1784357249000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10225536261441917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1177\/10225536261441917"],"URL":"https:\/\/doi.org\/10.1177\/10225536261441917","relation":{},"ISSN":["1022-5536","2309-4990"],"issn-type":[{"value":"1022-5536","type":"print"},{"value":"2309-4990","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"article-number":"10225536261441917"}}